Concepedia

Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial

Helmut Oettle, Hanno Riess, Jens Stieler, Gerhard Heil, Ingo Schwaner, Jörg Seraphin, Martin Görner, Matthias Mölle, Tim F. Greten, Volker Lakner,

Journal of Clinical Oncology · 2014 · 476 citations · 25 references

DOI

Abstract

Second-line OFF significantly extended the duration of overall survival when compared with FF alone in patients with advanced gemcitabine-refractory pancreatic cancer.

References

25

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy, Françoise Desseigne, Marc Ychou et al. · New England Journal of Medicine · 2011 · 7.6K citations · Full text

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena et al. · New England Journal of Medicine · 2013 · 6.5K citations

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Howard A. Burris, Malcolm J. Moore, John Sahl Andersen et al. · Journal of Clinical Oncology · 1997 · 5.8K citations

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Malcolm J. Moore, David Goldstein, John Hamm et al. · Journal of Clinical Oncology · 2007 · 3.8K citations

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group

Uwe Pelzer, Ingo Schwaner, Jens Stieler et al. · European Journal of Cancer · 2011 · 379 citations

, , +7